Streetwise Biotech / Pharmaceuticals Articles



Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results
Source: Streetwise Reports(11/8/19)
Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. More >


Could There Finally Be an Effective Treatment for Alzheimer's Disease?
Source: Streetwise Reports(11/6/19)
ProMIS' preclinical treatment could possibly outshine Biogen's candidate. More >


Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance
Source: Streetwise Reports(11/6/19)
Aquestive Therapeutics shares traded 20% higher today after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. More >


RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia
Source: Streetwise Reports(11/4/19)
Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/20. More >


BeiGene Shares Up 35% on Amgen's $2.7 Billion Investment and China Partnership
Source: Streetwise Reports(11/1/19)
Shares of BeiGene Ltd. traded 35% higher today to a new a 52-week intraday high after announcing a commercialization agreement for of XGEVA (denosumab), KYPROLIS (carfilzomib), and BLINCYTO (blinatumomab) with Amgen Inc. in China. As part of the partnership, Amgen will invest $2.7 billion in BeiGene for 20.5% equity ownership. More >


IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data
Source: Streetwise Reports(10/28/19)
Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. More >


Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses'
Source: Streetwise Reports(10/23/19)
The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report. More >


Biotech Develops Antibodies Targeting TDP-43 in Neurodegenerative Diseases
Source: Streetwise Reports(10/23/19)
These therapeutic candidates add to those already in the firm's pipeline. More >


Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings
Source: Streetwise Reports(10/22/19)
Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings today. More >


Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis
Source: Streetwise Reports(10/21/19)
The details of this study and a second one are outlined in a ROTH Capital Partners report. More >


Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher
Source: Streetwise Reports(10/18/19)
Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. More >


Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data
Source: Streetwise Reports(10/17/19)
Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. More >


Achillion Pharma Shares Open 75% Higher After Alexion Buyout Offer
Source: Streetwise Reports(10/16/19)
Shares of Achillion Pharmaceuticals are trading much higher today after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met. More >


Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho
Source: Streetwise Reports(10/16/19)
Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. More >


Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results
Source: Streetwise Reports(10/15/19)
Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100200% higher today and the stock was halted several times trading due to extreme price volatility. More >


Technical Analyst Expects Health Technologies Firm to Break Higher
Source: Clive Maund for Streetwise Reports(10/14/19)
Technical analyst Clive Maund outlines the reasons this stock might break higher. More >


Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million
Source: Streetwise Reports(10/14/19)
Shares of Cerecor Inc. are trading higher today after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. More >


Technical Analyst: As Antibiotic Resistance Rises, So May the Stock of This Livestock Feed Company
Source: Clive Maund for Streetwise Reports(10/12/19)
Technical analyst Clive Maund believes this stock could gain traction soon. More >


Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights
Source: Streetwise Reports(10/11/19)
Shares of Reata Pharmaceuticals are trading 12% higher today after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie. More >


Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid
Source: Streetwise Reports(10/10/19)
Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. More >


Biopharma Completes Enrollment in Phase 2a Plaque Psoriasis Trial
Source: Streetwise Reports(10/8/19)
Data from this study should be released by the end of this year. More >


Coverage Initiated on U.S.-Based Precision Therapy Developer
Source: Streetwise Reports(10/8/19)
The key reasons this story is compelling are given in an H.C. Wainwright & Co. report. More >


Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30%
Source: Streetwise Reports(10/7/19)
Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx used in the treatment of patients with cardiovascular and metabolic diseases. More >


PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial
Source: Streetwise Reports(10/3/19)
This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection. More >


Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'
Source: Streetwise Reports(9/30/19)
The latest clinical trial results are dissected in a ROTH Capital Partners report. More >


Showing Results: 1 to 25 of 997 Next

Notable Quotes

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe